Senior Group Leader

Research Group Home Page: 
Rosenfeld Group

Work address: 
Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE
Publications: 

Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models.

E-pub date: 31 Oct 2018


Enhanced detection of circulating tumor DNA by fragment size analysis.

E-pub date: 31 Oct 2018


Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients.

E-pub date: 31 Oct 2018


Effects of collection and processing procedures on plasma circulating cell-free DNA from cancer patients.

E-pub date: 31 Jul 2018


Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.

E-pub date: 01 Jun 2018


Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.

E-pub date: 16 Mar 2018


Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.

E-pub date: 15 Mar 2018


Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.

E-pub date: 01 Jan 2018


Are liquid biopsies a surrogate for tissue EGFR testing?

E-pub date: 01 Jan 2018


Societal challenges of precision medicine: Bringing order to chaos.

E-pub date: 31 Oct 2017


Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.

E-pub date: 17 Jul 2017


CVE: an R package for interactive variant prioritisation in precision oncology.

E-pub date: 25 May 2017


Liquid biopsies come of age: towards implementation of circulating tumour DNA.

E-pub date: 01 Apr 2017


Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

E-pub date: 01 Apr 2017


Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.

E-pub date: 31 Dec 2016


Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.

E-pub date: 31 Oct 2016


Consensus on precision medicine for metastatic cancers: a report from the MAP conference.

E-pub date: 31 Aug 2016


Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

E-pub date: 06 Jun 2016


The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

E-pub date: 10 May 2016


Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

E-pub date: 04 Nov 2015


Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.

E-pub date: 01 Apr 2015


Circulating tumor-derived DNA is shorter than somatic DNA in plasma.

E-pub date: 17 Mar 2015


Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.

E-pub date: 01 Feb 2015


Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis.

E-pub date: 31 Aug 2014


PTU-153 The Timing Of Oncogenic Events In The Evolution Of The Oesophageal Adenocarcinoma Genome And Implications For Clinical Diagnostics.

E-pub date: 01 Jun 2014


Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.

E-pub date: 31 Jan 2014


EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib–Letter.

E-pub date: 01 Nov 2013


Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension.

E-pub date: 01 Sep 2013


Circulating tumor DNA to monitor metastatic breast cancer.

E-pub date: 04 Jul 2013


Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.

E-pub date: 02 May 2013


Analysis of circulating tumor DNA to monitor metastatic breast cancer.

E-pub date: 28 Mar 2013


Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

E-pub date: 30 May 2012


Measuring single-cell gene expression dynamics in bacteria using fluorescence time-lapse microscopy.

E-pub date: 15 Dec 2011


MicroRNAs as a potential prognostic factor in gastric cancer.

E-pub date: 21 Sep 2011


A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.

E-pub date: 01 Nov 2010


Accurate molecular classification of renal tumors using microRNA expression.

E-pub date: 01 Sep 2010


Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression.

E-pub date: 31 Aug 2010


Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin.

E-pub date: 01 Jun 2010


MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors.

E-pub date: 31 Jul 2009


Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.

E-pub date: 20 Apr 2009


MicroRNAs accurately identify cancer tissue origin.

E-pub date: 01 Apr 2008


Accurate prediction of gene feedback circuit behavior from component properties.

E-pub date: 31 Aug 2007


Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.

E-pub date: 08 Jun 2007


Response delays and the structure of transcription networks.

E-pub date: 31 May 2003


Negative autoregulation speeds the response times of transcription networks.

E-pub date: 31 Oct 2002


Show all
Research Integrity Conflict of Interest Disclosure: 
Last revised: 
16/11/2018
Company Active Research funding Ownership Royalty payments Commitment to carry out work for a fee Ad hoc reimbursed work Travel Gifts/ other
Inivata Ltd. Yes No Yes Yes Yes No Yes No
Mission Therapeutics Yes No Yes No No No No No
Storm Therapeutics Yes No Yes No No No No No
AstraZeneca Yes Yes No No No No No No
Disclosure guidelines